Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...

Arch Biopartners (($TSE:ARCH)) announced an update on their ongoing clinical study. Arch Biopartners is conducting a Phase 2 global study titled ...

Sai Life Sciences Limited today announced the groundbreaking for a new CMC Process R&D Center at its integrated R&D campus in ...

Initial Clinical Data Expected in the First Half of 2026SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data on Vanoglipel (DA-1241), a ...

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favourable safety profile in difficult-to-treat scalp and genital psoriasis ...

An announcement from Ascletis Pharma, Inc. ( ($HK:1672) ) is now available. Ascletis Pharma Inc. announced it will present study results of its ...

The new center is designed to support both Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) engagement models, enabling flexible collaboration with global innovators from early ...

Shares in Avacta rose on Monday after the clinical stage biopharmaceutical company presented preclinical data showing its novel dual payload pre|CISION technology at a oncology conference in Boston.

Optimizing the aging process isn’t a new concept for researchers. Scientists have long studied the world’s Blue Zones ...

NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...

Given that price erosion in the North American market is expected to continue in the near term, some brokerages have cut ...